$ATXI
Avenue Therapeutics Inc Stock $atxi

$atxi Overview Financials Valuation SEC Filings Company Website

2018 Q1 Form 10-K Financial Statement

#000114420418012321 Filed on March 01, 2018

Income Statement

Concept	2018 Q1	2017 Q4	2017 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$990.0K	$1.100M	$850.0K
YoY Change	167.57%	266.67%	325.0%
% of Gross Profit
Research & Development	$9.439M	$5.220M	$2.000M
YoY Change	6996.99%	2385.71%	992.9%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$9.439M	$6.325M	$2.848M
YoY Change	1772.82%	1125.78%	643.6%
Operating Profit	-$10.43M		-$2.848M
YoY Change	1968.45%		643.6%
Interest Expense	$0.00	$80.00K	$106.0K
YoY Change	-100.0%	-126.67%	19.1%
% of Operating Profit
Other Income/Expense, Net	$0.00	$82.00K	-$100.0K
YoY Change	-100.0%	-127.42%	-37.89%
Pretax Income	-$10.38M	-$6.240M	-$2.950M
YoY Change	1472.73%	660.98%	446.3%
Income Tax
% Of Pretax Income
Net Earnings	-$10.38M	-$6.243M	-$2.948M
YoY Change	1469.89%	666.01%	441.91%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.028M	-$624.6K	-$295.9K
COMMON SHARES
Basic Shares Outstanding	10.28M shares	10.27M shares	10.04M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q1	2017 Q4	2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$14.96M	$21.78M	$26.05M
YoY Change		10790.0%	86733.33%
Cash & Equivalents	$14.96M	$11.78M	$16.05M
Short-Term Investments	$0.00	$10.00M	$10.00M
Other Short-Term Assets	$310.0K	$390.0K	$130.0K
YoY Change	34.78%		333.33%
Inventory
Prepaid Expenses			$126.0K
Receivables
Other Receivables
Total Short-Term Assets	$15.27M	$22.17M	$26.18M
YoY Change	6539.13%	10985.0%	43533.33%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$3.000K	$0.00	-$4.000K
YoY Change	-25.0%	-100.0%
TOTAL ASSETS
Total Short-Term Assets	$15.27M	$22.17M	$26.18M
Total Long-Term Assets	$3.000K	$0.00	-$4.000K
Total Assets	$15.27M	$22.17M	$26.18M
YoY Change	6426.92%	11153.81%	43526.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.909M	$1.545M	$1.910M
YoY Change	349.31%	362.57%	377.5%
Accrued Expenses	$2.010M	$50.00K	$80.00K
YoY Change	1.52%	-97.14%	-94.2%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Short-Term Liabilities	$5.920M	$2.790M	$1.990M
YoY Change	-24.35%	-56.54%	-58.19%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.920M	$2.790M	$1.990M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$5.920M	$2.790M	$1.990M
YoY Change	-35.22%	-66.96%	-73.64%
SHAREHOLDERS EQUITY
Retained Earnings	-$31.04M	-$20.66M	-$14.42M
YoY Change	242.43%	145.88%
Common Stock	$40.39M	$38.94M	$38.60M
YoY Change	25144.38%	36633.96%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.353M	$19.38M	$24.19M
YoY Change
Total Liabilities & Shareholders Equity	$15.27M	$22.17M	$26.18M
YoY Change	6426.92%	11153.81%	43526.67%

Cashflow Statement

Concept	2018 Q1	2017 Q4	2017 Q3
OPERATING ACTIVITIES
Net Income	-$10.38M	-$6.243M	-$2.948M
YoY Change	1469.89%	666.01%	441.91%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$6.819M	-$4.270M	-$1.870M
YoY Change	19955.88%	6000.0%	325.0%
INVESTING ACTIVITIES
Capital Expenditures		$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$10.00M	$0.00	-$10.00M
YoY Change
Cash From Investing Activities	$10.00M	$0.00	-$10.00M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	-6.750M
YoY Change	-100.0%	-100.0%	-1600.0%
NET CHANGE
Cash From Operating Activities	-6.819M	-4.270M	-1.870M
Cash From Investing Activities	10.00M	0.000	-10.00M
Cash From Financing Activities	0.000	0.000	-6.750M
Net Change In Cash	3.181M	-4.270M	-18.62M
YoY Change	-1714.72%	-2611.76%	-186300.0%
FREE CASH FLOW
Cash From Operating Activities	-$6.819M	-$4.270M	-$1.870M
Capital Expenditures		$0.00
Free Cash Flow		-$4.270M
YoY Change		6000.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2017	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2017	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2017Q2	dei	Entity Public Float EntityPublicFloat	50811757	USD
CY2017	dei	Trading Symbol TradingSymbol	ATXI
CY2018Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10277083	shares
CY2016	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	57000	USD
CY2017	atxi	Accrued Interest Related Party AccruedInterestRelatedParty	-46000	USD
CY2016	atxi	Accrued Interest Related Party AccruedInterestRelatedParty	181000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6802000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1632000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11782000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	197000	USD
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	10000000	USD
CY2016Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2017Q4	atxi	Accounts Payable And Accrued Expenses Related Party Current AccountsPayableAndAccruedExpensesRelatedPartyCurrent	53000	USD
CY2016Q4	atxi	Accounts Payable And Accrued Expenses Related Party Current AccountsPayableAndAccruedExpensesRelatedPartyCurrent	1348000	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1331000	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	997000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-2377000	USD
CY2016	us-gaap	Interest Expense InterestExpense	420000	USD
CY2016	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	192000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-3177000	USD
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.11
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2860526	shares
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6698000	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3620000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-11421000	USD
CY2017	us-gaap	Interest Expense InterestExpense	294000	USD
CY2017	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	81000	USD
CY2017	atxi	Fair Value Adjustments Of Convertible Notes Payable FairValueAdjustmentsOfConvertibleNotesPayable	99000	USD
CY2017	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	451000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-12258000	USD
CY2016	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	USD
CY2017	us-gaap	Investment Income Interest InvestmentIncomeInterest	88000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	604000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	28000	USD
CY2017	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	174000	USD
CY2016	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	123000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2231000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	15000	USD
CY2017	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	337000	USD
CY2016	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	829000	USD
CY2017	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-57000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	28387000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1815000	USD
CY2017	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	11585000	USD
CY2016	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	183000	USD
CY2017	us-gaap	Interest Paid Net InterestPaidNet	303000	USD
CY2016	us-gaap	Interest Paid Net InterestPaidNet	183000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	388000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	0	USD
CY2017	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	3715000	USD
CY2016	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	0	USD
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	37950000	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2017	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	1000000	USD
CY2016	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2017	atxi	Warrants Issued WarrantsIssued	750000	USD
CY2016	atxi	Warrants Issued WarrantsIssued	0	USD
CY2017	atxi	Extinguishment Of Fortress Compensation Accrual ExtinguishmentOfFortressCompensationAccrual	632000	USD
CY2016	atxi	Extinguishment Of Fortress Compensation Accrual ExtinguishmentOfFortressCompensationAccrual	0	USD
CY2017	atxi	Interest On Fortress Note On Modification InterestOnFortressNoteOnModification	300000	USD
CY2016	atxi	Interest On Fortress Note On Modification InterestOnFortressNoteOnModification	0	USD
CY2017	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	200000	USD
CY2016	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2017	atxi	Change Fair Value Of Convertible Note Warrents ChangeFairValueOfConvertibleNoteWarrents	15000	USD
CY2016	atxi	Change Fair Value Of Convertible Note Warrents ChangeFairValueOfConvertibleNoteWarrents	0	USD
CY2017	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	10000000	USD
CY2016	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-10000000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2017	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	3000000	USD
CY2016	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2017	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0	USD
CY2016	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	1000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-5226000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	29000	USD
	atxi	Fair Value Adjustments Of Convertible Notes Payable FairValueAdjustmentsOfConvertibleNotesPayable	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	73000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	491000	USD
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	511000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
	atxi	Accrued Interest Related Party AccruedInterestRelatedParty	165000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-895000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3909000	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	14000	USD
	us-gaap	Interest Paid Net InterestPaidNet	60000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	0	USD
	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
	atxi	Warrants Issued WarrantsIssued	0	USD
	atxi	Extinguishment Of Fortress Compensation Accrual ExtinguishmentOfFortressCompensationAccrual	0	USD
	atxi	Interest On Fortress Note On Modification InterestOnFortressNoteOnModification	0	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
	atxi	Change Fair Value Of Convertible Note Warrents ChangeFairValueOfConvertibleNoteWarrents	0	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3000000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	0	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	300000	USD
CY2017Q3	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	5000000	USD
CY2016Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	250000	shares
CY2016Q3	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.025	pure
CY2015Q4	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	3000000	USD
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	200000	USD
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8	pure
CY2017Q3	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	3500000	USD
CY2017Q3	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	100000	USD
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2000000	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q2	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	166666	shares
CY2017Q2	us-gaap	Share Price SharePrice	6.00
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	20000	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.29
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0183	pure
CY2017Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	20000	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	20000	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.29
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.29
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y7M17D
CY2017Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	0	USD
CY2016Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	300000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	388000	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	0	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10265083	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10265083	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3257936	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3257936	shares
CY2017Q4	atxi	Common Stock Shares Issuable CommonStockSharesIssuable	273837	shares
CY2016Q4	atxi	Common Stock Shares Issuable CommonStockSharesIssuable	83532	shares
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	961000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	842000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4843000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	0	USD
	us-gaap	Interest Expense InterestExpense	215000	USD
	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	168000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.93
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2702403	shares
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 3.3pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0px; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i>Use of Estimates</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 3.3pt; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong><i> </i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	1103000	USD
CY2016	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	49000	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	3040000	USD
CY2017	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0px; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0px; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><i>Valuation of Warrant Related to NSC Note</i></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0px; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.25in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In accordance with ASC 815 <i>Derivatives and Hedging</i>, the Company classified the fair value of the warrant (“Contingently Issuable Warrants”) that it may be obligated to issue to National Securities, Inc. (“NSC”), in connection with the transfer on October 31, 2015 of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.0</font> million of indebtedness to NSC, as a derivative liability as there was a potential that the Company would not have a sufficient number of authorized common shares available to settle this instrument. The Company valued these Contingently Issuable Warrants using a Black-Scholes model and used estimates for an expected dividend yield, a risk-free interest rate, and expected volatility together with management’s estimate of the probability of issuance of the Contingently Issuable Warrants. At each reporting period, as long as the Contingently Issuable Warrants were potentially issuable and there was a potential for an insufficient number of authorized shares available to settle the Contingently Issuable Warrants, the Contingently Issuable Warrants had to be revalued and any difference from the previous valuation date would be recognized as a change in fair value in the Company’s statement of operations. On June 26, 2017, the warrants were issued (See Note 9).</div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	100000	USD
CY2017	atxi	Stock Issuance Common Stock Issuable During Period Value StockIssuanceCommonStockIssuableDuringPeriodValue	1103000	USD
CY2017	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	34235000	USD
CY2016	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	0	USD
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	3000000	USD
CY2017	atxi	Stock Issued During Period Conversion Of Msa Fees Into Common Value StockIssuedDuringPeriodConversionOfMsaFeesIntoCommonValue	1000000	USD
CY2017	atxi	Stock Issued During Period Issuance Of Warrants Under Nsc Note StockIssuedDuringPeriodIssuanceOfWarrantsUnderNscNote	750000	USD
CY2017	atxi	Share Issued During Period Valueon Exercise Of Warrants ShareIssuedDuringPeriodValueonExerciseOfWarrants	0	USD
CY2017	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	299000	USD
CY2017	atxi	Change In Fair Value Of Convertible Notes Warrants ChangeInFairValueOfConvertibleNotesWarrants	15000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1545000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	334000	USD
CY2017Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	215000	USD
CY2016Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	0	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	977000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	172000	USD
	atxi	Stock Issued During Period Value Issuable To Parent New Issues StockIssuedDuringPeriodValueIssuableToParentNewIssues	0	USD
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	22000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	29000	USD
	atxi	Stock Issuance Common Stock Issuable During Period Value StockIssuanceCommonStockIssuableDuringPeriodValue	40000	USD
CY2016	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5000	USD
CY2016	atxi	Common Stock Converted To Preferred Shares Value CommonStockConvertedToPreferredSharesValue	0	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	28000	USD
CY2016	atxi	Stock Issuance Common Stock Issuable During Period Value StockIssuanceCommonStockIssuableDuringPeriodValue	49000	USD
CY2016	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	18000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	604000	USD
CY2017	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	948000	USD
CY2017	atxi	Modification To Interest On Fortress Note ModificationToInterestOnFortressNote	300000	USD
CY2017	us-gaap	Stockholders Equity Period Increase Decrease StockholdersEquityPeriodIncreaseDecrease	632000	USD
CY2017	atxi	Agreement Description Terms AgreementDescriptionTerms	(i) issue annually to Fortress, on the anniversary date of the Founders Agreement, shares of common stock equal to two and one half percent (2.5%) of the fully-diluted outstanding equity of Avenue at the time of issuance; (ii) pay an equity fee in shares of Avenue common stock, payable within five (5) business days of the closing of any equity or debt financing for Avenue or any of its respective subsidiaries that occurs after the effective date of the Founders Agreement and ending on the date when Fortress no longer has majority voting control in Avenues voting equity, equal to two and one half percent (2.5%) of the gross amount of any such equity or debt financing; and (iii) pay a cash fee equal to four and one half percent (4.5%) of Avenues annual net sales, payable on an annual basis, within ninety (90) days of the end of each calendar year. In the event of a change in control (as it is defined in the Founders Agreement), Fortress will be paid a one-time change in control fee equal to five (5x) times the product of (i) net sales for the twelve (12) months immediately preceding the change in control and (ii) four and one-half percent (4.5%).
CY2017	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2016	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2017	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	0	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	22000	USD
CY2017	atxi	Common Stock Issuable For Founder Agreement CommonStockIssuableForFounderAgreement	1103000	USD
CY2016	atxi	Common Stock Issuable For Founder Agreement CommonStockIssuableForFounderAgreement	49000	USD
	atxi	Common Stock Issuable For Founder Agreement CommonStockIssuableForFounderAgreement	40000	USD
CY2017	atxi	Issuance Of Common Shares For Founders Agreement IssuanceOfCommonSharesForFoundersAgreement	948000	USD
CY2016	atxi	Issuance Of Common Shares For Founders Agreement IssuanceOfCommonSharesForFoundersAgreement	5000	USD
	atxi	Issuance Of Common Shares For Founders Agreement IssuanceOfCommonSharesForFoundersAgreement	0	USD
CY2017	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	0	USD
CY2016	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	58000	USD
	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	0	USD
CY2017	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
CY2016	us-gaap	Other Noncash Expense OtherNoncashExpense	12000	USD
	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
CY2017	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	0	USD
CY2016	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	0	USD
	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	3000000	USD
CY2017	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2016	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	200000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2017	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	0	USD
CY2016	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	58000	USD
	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	0	USD
CY2017	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2016	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	256000	USD
CY2017	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable	0	USD
CY2016	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable	0	USD
	us-gaap	Proceeds From Unsecured Notes Payable ProceedsFromUnsecuredNotesPayable	3000000	USD
CY2017	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	637000	USD
CY2016	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1673000	USD
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1165000	USD
CY2017	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	3485000	USD
CY2016	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
CY2017	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	0	USD
CY2016	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	0	USD
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	114000	USD
CY2017	atxi	Retirement Of Common Shares RetirementOfCommonShares	0	USD
CY2016	atxi	Retirement Of Common Shares RetirementOfCommonShares	18000	USD
	atxi	Retirement Of Common Shares RetirementOfCommonShares	0	USD
CY2017	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2016	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Stock Issued1 StockIssued1	1000	USD
CY2017	atxi	Service Agreement Expenses ServiceAgreementExpenses	500000	USD
CY2016	atxi	Service Agreement Expenses ServiceAgreementExpenses	500000	USD
CY2015	atxi	Service Agreement Expenses ServiceAgreementExpenses	400000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	504000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	1744000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	2848000	USD
CY2017Q4	us-gaap	Operating Expenses OperatingExpenses	6325000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-157000	USD
CY2017Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-662000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-661000	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-100000	USD
CY2017Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	82000	USD
CY2016	atxi	Effective Income Tax Rate Reconciliation Change In Enacted Federal Tax Rate Percent EffectiveIncomeTaxRateReconciliationChangeInEnactedFederalTaxRatePercent	0	pure
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-2406000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-2948000	USD
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	-6243000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.70
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
CY2017Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.63
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	840000	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	638000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	383000	USD
CY2016Q4	us-gaap	Operating Expenses OperatingExpenses	516000	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-207000	USD
CY2016Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-133000	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-161000	USD
CY2016Q4	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-299000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-1047000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-771000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-544000	USD
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	-815000	USD
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.28
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.19
CY2016Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2017	atxi	Effective Income Tax Rate Reconciliation Change In Enacted State Tax Rate Percent EffectiveIncomeTaxRateReconciliationChangeInEnactedStateTaxRatePercent	0.01	pure
CY2016	atxi	Effective Income Tax Rate Reconciliation Change In Enacted State Tax Rate Percent EffectiveIncomeTaxRateReconciliationChangeInEnactedStateTaxRatePercent	-0.01	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.04	pure
CY2017	atxi	Effective Income Tax Rate Reconciliation Change In Enacted Federal Tax Rate Percent EffectiveIncomeTaxRateReconciliationChangeInEnactedFederalTaxRatePercent	-0.2	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.08	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.03	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.01	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.01	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.21	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.38	pure
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4220000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2080000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	70000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments	226000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Derivative Instruments DeferredTaxAssetsDerivativeInstruments	73000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1064000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1064000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	8000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	78000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	154000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	33000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	5742000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3328000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5742000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3318000	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	0	USD
CY2016Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	10000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2017	atxi	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Granted Contractuallterm1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingGrantedContractuallterm1	P5Y
CY2016Q3	us-gaap	Stock Repurchased And Retired During Period Shares StockRepurchasedAndRetiredDuringPeriodShares	33333	shares
CY2017Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	200000	USD
CY2017Q2	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	49748	shares
CY2017Q3	us-gaap	Share Price SharePrice	1.85
CY2017Q3	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	37000	USD
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	6.29
CY2015Q1	us-gaap	Stockholders Equity StockholdersEquity	0	USD
CY2016Q4	us-gaap	Notes Payable NotesPayable	2826000	USD
CY2017Q4	us-gaap	Notes Payable NotesPayable	0	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	-5135000	USD
CY2017Q2	atxi	Share Based Compensation Allocation Percentage ShareBasedCompensationAllocationPercentage	1	pure
CY2017	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	984999	shares
CY2016	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	524999	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	366666	shares
CY2017Q3	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	5000000	USD
CY2017	atxi	Extend Loan Modification Reduction To Interest Expense ExtendLoanModificationReductionToInterestExpense	300000	USD
CY2015Q4	us-gaap	Notes Payable NotesPayable	2703000	USD

Files In Submission

Name	View Source	Status
0001144204-18-012321-index-headers.html	Edgar Link	pending
0001144204-18-012321-index.html	Edgar Link	pending
0001144204-18-012321.txt	Edgar Link	pending
0001144204-18-012321-xbrl.zip	Edgar Link	pending
atxi-20171231.xml	Edgar Link	completed
atxi-20171231.xsd	Edgar Link	pending
atxi-20171231_cal.xml	Edgar Link	unprocessable
atxi-20171231_def.xml	Edgar Link	unprocessable
atxi-20171231_lab.xml	Edgar Link	unprocessable
atxi-20171231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv486678_10k.htm	Edgar Link	pending
tv486678_ex10-7.htm	Edgar Link	pending
tv486678_ex10-9.htm	Edgar Link	pending
tv486678_ex23-1.htm	Edgar Link	pending
tv486678_ex31-1.htm	Edgar Link	pending
tv486678_ex31-2.htm	Edgar Link	pending
tv486678_ex32-1.htm	Edgar Link	pending
tv486678_ex32-2.htm	Edgar Link	pending
tv486678_img01.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ATXI
Avenue Therapeutics Inc Stock $atxi

2018 Q1 Form 10-K Financial Statement

#000114420418012321 Filed on March 01, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATXI Avenue Therapeutics Inc Stock $atxi

2018 Q1 Form 10-K Financial Statement

#000114420418012321 Filed on March 01, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATXI
Avenue Therapeutics Inc Stock $atxi